Skip to main content
SpringerLink
Log in

Incidence and outcome of overt gastrointestinal bleeding in patients undergoing bone marrow transplantation

  • Gastrointestinal Oncology
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The purpose of this study was to determine the prevalence, clinical patterns, and outcomes of gastrointestinal bleeding in consecutive patients treated at one bone marrow transplant center. We reviewed the clinical course of 579 consecutive bone marrow transplant recipients who underwent therapy from January 1986 through December 1993. These patients were evaluated for overt gastrointestinal bleeding, defined as hematemesis, melena, hematochezia, or a combination. Overt gastrointestinal bleeding was identified in 43 of 579 patients (7.4%), including 25 men and 18 women undergoing transplantation for hematologic disorders (N=29) and solid tumors (N=14). After high-dose cytotoxic chemotherapy, patients were given allogeneic (N=10) or autologous (N=33) hematopoietic progenitor cell support obtained from bone marrow, peripheral blood, or both. H2 blockers, sucralfate, or a combination were administered to all patients as prophylactic therapy. Bleeding manifestations included hematemesis (N=24), melena (N=8), hematochezia (N=7), and combinations (N=4). The median time from bone marrow infusion to the onset of overt gastrointestinal bleeding was 7.5 days (range: 0–45 days). Fourteen patients had evidence of orthostatic hypotension attributable to gastrointestinal bleeding. Esophagogastroduodenoscopy was performed in 26 patients; 18 had diffuse esophagitis and gastritis. Two patients with bleeding ulcers underwent successful electrocautery. Colonoscopy was performed in five patients and revealed a cecal ulcer in one subject, tumor recurrence in one patient, and colitis in another. No patients underwent surgical intervention. Only one patient died as a result of gastrointestinal bleeding. Overt gastrointestinal bleeding is uncommon in patients undergoing bone marrow transplantation; most episodes are self-limited and do not contribute to overall mortality. Endoscopy is primarily diagnostic as most patients do not have lesions amenable to therapeutic procedures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bortin MM, Horowitz MM, Rimm AA: Increasing utilization of allogeneic bone marrow transplantation: Results of the 1988–1990 survey. Ann Intern Med 116:505–512, 1992

    Google Scholar 

  2. O'Reilly RJ, Brochstein J, Dinsmore R, Kirkpatrick D: Marrow transplantation for congenital disorders. Semin Hematol 21:188–221, 1984

    Google Scholar 

  3. Armitage JO: Bone marrow transplantation. N Engl J Med 330:827–838, 1994

    Google Scholar 

  4. Memoli D, Spitzer TR, Cottler-Fox M, Cahill R, Benjamin S, Deeg HJ: Acute esophageal stricture after bone marrow transplantation. Bone Marrow Transplant 3:513–516, 1988

    Google Scholar 

  5. Spencer GD, Hackman RC, McDonald GB, Amos DE, Cunningham BA, Meyers JD, Thomas ED: A prospective study of unexplained nausea and vomiting after bone marrow transplant. Transplantation 42:602–607, 1986

    Google Scholar 

  6. McDonald GB, Sharma P, Hackman RC, Meyers JD, Thomas ED: Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 88:1111–1117, 1985

    Google Scholar 

  7. Bortin MM, Ringden O, Horowitz MM, Rozman C, Weiner RS, Rimm AA: Temporal relationships between major complications of bone marrow transplantation for leukemia. Bone Marrow Transplant 4:339–344, 1989

    Google Scholar 

  8. McDonald GB, Shulman HM, Sullivan KM, Spencer GD: Intestinal and hepatic complications of human bone marrow transplantation. Part I and Part II. Gastroenterology 90:460–477, 770–784, 1986

    Google Scholar 

  9. Wheeler RR, Peacock JE Jr, Cruz JM, Richter JE: Esophagitis in the immunocompromised host: Role of esophagoscopy in diagnosis. Rev Infect Dis 9:88–96, 1987

    Google Scholar 

  10. Goodman ZD, Boitnott JK, Yardley JH: Perforation of the colon associated with cytomegalovirus infection. Dig Dis Sci 24:376–380, 1979

    Google Scholar 

  11. West JC, Armitage JO, Mitros FA, Klassen LW, Corry RJ, Ray T: Cytomegalovirus cecal erosion causing massive hemorrhage in a bone marrow transplant recipient. World J Surg 6:251–255, 1982

    Google Scholar 

  12. Erice A, Jordan MC, Chace BA, Fletcher C, Chinnock BJ, Balfour HH Jr: Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunosuppressed hosts. J Am Med Assoc 257:3082–3087, 1987

    Google Scholar 

  13. Spencer GD, Shulman HM, Myerson D, Thomas ED, McDonald GB: Diffuse intestinal ulceration after marrow transplantation: A clinical-pathologic study of 13 patients. Hum Pathol 17:621–633, 1986

    Google Scholar 

  14. Slavin RE, Dias MA, Saral R: Cytosine arabinoside-induced gastrointestinal toxic alteration in sequential chemotherapeutic protocols. A clinical-pathologic study of 33 patients. Cancer 42:1747–1759, 1978

    Google Scholar 

  15. Phillips TL, Fu KK: The interaction of drug and radiation affects on normal tissues. Int J Radiat Oncol Biol Physiol 4:59–64, 1978

    Google Scholar 

  16. Wolford JL, McDonald GB: A problem-oriented approach to intestinal and liver disease after marrow transplantation. J Clin Gastroenterol 10:419–433, 1988

    Google Scholar 

  17. Snover DC, Weisdorf SA, Vercellotti GM, Rank B, Hutton S, McGlave P: A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 16:387–392, 1985

    Google Scholar 

  18. Schiller GJ, Gale RP: A critical reappraisal of gastrointestinal complications of allogeneic bone marrow transplantation. Cell Transplant 1:265–269, 1992

    Google Scholar 

  19. Lazarus HM, Creger RJ, Gerson SL: Infectious emergencies in oncology patients. Semin Oncol 16:543–560, 1989

    Google Scholar 

  20. Gerson SL, Lazarus HM: Hematopoietic emergencies. Semin Oncol 16:532–542, 1989

    Google Scholar 

  21. Rowe JM, Ciobanu N, Ascensao J, Stadtmauer EA, Weiner R, Schenkein DP, McGlave P, Lazarus HM: Recommended guidelines for the management of autologous and allogeneic marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med 120:143–158, 1994

    Google Scholar 

  22. Lazarus HM, Bryson JC, Lemon E, Pritchard JF, Blumer J: Antimetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple-day cisplatin prior to autologous bone marrow transplantation. J Natl Cancer Inst 82:1776–1778, 1990

    Google Scholar 

  23. Lazarus HM, Reed MD, Spitzer TR, Rabaa MS, Blumer JL: High-dose IV thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71:689–695, 1987

    Google Scholar 

  24. Spitzer TR, Lazarus HM, Creger RJ, Berger NA: High dose melphalan, misonidazole, and autologous bone marrow transplantation for the treatment of metastatic colorectal carcinoma—a phase I study. Am J Clin Oncol 12:145–151, 1989

    Google Scholar 

  25. Lazarus HM, Spitzer TR, Creger RJ: Phase I trial of high-dose etoposide, high-dose cisplatin, and re-infusion of autologous bone marrow for lung cancer. Am J Clin Oncol 13:107–112, 1990

    Google Scholar 

  26. Lazarus HM, Andersen J, Chen MG, Variakojis D, Mansour EG, Oette D, Arce CA, Oken MM, Gerson SL: Recombinant GM-CSF after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: Blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group trial. Blood 78:830–837, 1991

    Google Scholar 

  27. Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, Loehrer PJ, Trump DL: High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group Protocol. J Clin Oncol 10:558–563, 1992

    Google Scholar 

  28. Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D, Soegiarso W, Brodsky I: High-dose carmustine, etoposide, cisplatin (BEP) and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 10:1682–1689, 1992

    Google Scholar 

  29. Stadtmauer E, Schenkein D, Miller K, Sickles C, Biggs D, Powlis W, Friedenberg W, Winter J, Tallman M, Lazarus H: GM-CSF mobilized peripheral blood progenitor cells (PSC) and GM-CSF post infusion after high-dose melphalan, cyclophosphamide and total body irradiation (TBI) for advanced relapsed multiple myeloma. Blood 82:264a, 1993 (abstract 1043)

    Google Scholar 

  30. Phillips GL, Herzig RH, Lazarus HM, Fay JW, Wolff SN, Mill WB, Lin H, Thomas PR, Glasgow GP, Shina DC, Herzig GP: Treatment of relapsed lymphoma with cyclophosphamide, total body irradiation and autologous bone marrow transplantation. N Engl J Med 310:1557–1561, 1984

    Google Scholar 

  31. Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin H-S, Shina DC, Glasgow GP, Griffith RC, Lamb CW, Herzig GP: The treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous marrow transplantation. Blood 73:2086–2092, 1989

    Google Scholar 

  32. Phillips GL, Fay JW, Herzig RH, Lazarus HM, Wolff SN, Lin H-S, Shina DC, Glasgow GP, Griffith RC, Lamb CW, Herzig GP: The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 75:831–838, 1990

    Google Scholar 

  33. Snyder DS, Chao NJ, Amylon MD, Taguchi J, Long GW, Negrin RS, Nademannee AP, O'Donnell MR, Schmidt GM, Stein AS, Parker PM, Smith EP, Stepan DE, Molina A, Lipsett JA, Hoppe RT, Niland JC, Dagis AC, Wong RM, Forman SJ, Blume KG: Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 82:2920–2928, 1993

    Google Scholar 

  34. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei E III: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measureable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102–110, 1992

    Google Scholar 

  35. Herzig RH, Coccia PF, Lazarus HM, Strandjord SE, Graham-Pole J, Cheung N-K, Gordon EM, Gross S, Spitzer TR, Warkentin PI, Fay JW, Phillips GL, Herzig GP: Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation. Semin Oncol 12:184–186, 1985

    Google Scholar 

  36. Stein J, Strandjord S, Saarinen U, Warkentin P, Gerson S, Lazarus H, von Hoff D, Coccia P, Cheung NK:In vitro treatment of autologous bone marrow for neuroblastoma patients with anti GD2 monoclonal antibody and human complement: a pilot study. Prog Clin Biol Res 271:237–248, 1988

    Google Scholar 

  37. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382–1388, 1987

    Google Scholar 

  38. Cassileth PA, Andersen J, Lazarus HM, Colvin OM, Bennett JM, Stadtmauer EA, Kaizer H, Weiner RS, Edelstein M, Oken MM: Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 11:314–319, 1993

    Google Scholar 

  39. Deeg HJ, Loughran TP Jr, Storb R, Kennedy MS, Sullivan KM, Doney K, Appelbaum FR, Thomas ED: Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 40:162–166, 1985

    Google Scholar 

  40. Kennedy MS, Deeg HJ, Storb R, Doney K, Sullivan KM, Witherspoon RP, Appelbaum FR, Stewart P, Sanders J, Buckner CD, Martin P, Weiden P, Thomas ED: Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. Am J Med 78:978–983, 1985

    Google Scholar 

  41. Garewal HS, Durie BG: Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. Scand J Haematol 35:497–500, 1985

    Google Scholar 

  42. Benson K, Fields K, Hiemenz J, Zorsky P, Ballester O, Perkins J, Elfenbein G: The platelet-refractory bone marrow transplant patient: Prophylaxis and treatment of bleeding. Semin Oncol 20(suppl 6):102–109, 1993

    Google Scholar 

  43. Johnson MC, Pinkas H, Elfenbein GJ: Endoscopy in the bone marrow transplant patient presenting with gastrointestinal symptoms: Is it useful? Gastrointest Endosc 40:P42, 1994 (abstract 109)

  44. Vishny ML, Blades EW, Creger RJ, Lazarus HM: Role of upper endoscopy in evaluation of upper gastrointestinal symptoms in patients undergoing bone marrow transplantation. Cancer Invest 12:384–389, 1994

    Google Scholar 

  45. Laine L: Bipolar/multipolar electrocoagulation. Gastrointest Endosc 36:S38-S41, 1990

    Google Scholar 

  46. Consensus Conference. Therapeutic endoscopy and bleeding ulcers. J Am Med Assoc 262:1369–1372, 1989

    Google Scholar 

  47. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd TJ, Roy P, Lacroix J, Griffith L, Willan A: Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 330:377–381, 1994

    Google Scholar 

  48. Maton PN: Omeprazole. N Engl J Med 324:965–975, 1991

    Google Scholar 

  49. Wolford JL, McDonald GB: Gastrointestinal bleeding after marrow transplant: A prospective study of risk factors, etiology, and outcome. Gastroenterology 92:1697, 1987 (abstract)

    Google Scholar 

  50. Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, Tepler I, Mazanet R, Lynch C, Pap S, Pelaez J, Reich E, Critchlow J, Demetri G, Bibbo J, Schnipper L, Griffin J, Frei E III, Antman K: Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 79:3036–3044, 1992

    Google Scholar 

  51. Bensinger W, Petersen FB, Banaji M, Buckner CD, Clift R, Slichter SJ, Storb R, Thomas ED: Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute nonlymphocytic leukemia in first complete remission. Bone Marrow Transplant 4:409–414, 1989

    Google Scholar 

Download references

Author information

Author notes

  1. Suman Kaur MD

    Present address: Rush-Presbyterian Hospital, Chicago, Illinois

Authors and Affiliations

  1. From the Department of Medicine, Divisions of Gastroenterology and Hematology-Oncology, Ireland Cancer Center University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio

    Suman Kaur MD, Gregory Cooper MD, Sandra Fakult MD &  Hillard M. Lazarus MD, FACP

Authors
  1. Suman Kaur MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory Cooper MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandra Fakult MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hillard M. Lazarus MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaur, S., Cooper, G., Fakult, S. et al. Incidence and outcome of overt gastrointestinal bleeding in patients undergoing bone marrow transplantation. Digest Dis Sci 41, 598–603 (1996). https://doi.org/10.1007/BF02282348

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02282348

Key words

Search

Navigation